The recommendation of betula verrucosa is the first NICE approval for an under-the-tongue immunotherapy for these conditions. Unlike conventional treatments that merely mask symptoms, this ...

Around 5,700 people with early breast cancer are set to benefit from expanded access to a treatment combination designed to help prevent their cancer from returning, following our recommendation, ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing ...

A quick guide for care home managers More than half of older adults who live in care homes have tooth decay, compared to 40% of over 75s who do not live in care homes. Poor oral health can affect ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...

BMI: preventing ill health and premature death in black, Asian and other minority ethnic groups Public health guideline PH46 Published: 03 July 2013 ...

Hybrid closed loop (HCL) systems are recommended as an option for managing blood glucose levels in type 1 diabetes for adults who have an HbA1c of 58 mmol/mol (7.5%) or more, or have disabling ...

This guideline has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) [NG245] ...

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...

This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by ...

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection Technology appraisal guidance TA761 Published: 19 January 2022 ...